E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Under the partnership, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets.
imphoenix82
The NMPA clearance allows Adcentrx to include China-based clinical centres in its ongoing Phase 1a/1b trial evaluating the ADC in patients with late-stage solid tumours, including prostate cancer.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
